rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma
Authors Zhu J, Hao SG, Hu J, Zhuang JL, Wang C, Bai HT
Received 12 June 2019
Accepted for publication 19 August 2019
Published 13 September 2019 Volume 2019:11 Pages 8371—8377
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Ahmet Emre Eskazan
Jun Zhu,1 Si-Guo Hao,2 Jiong Hu,3 Jing-Li Zhuang,4 Chun Wang,1 Hai-Tao Bai1
1Department of Haematology, Shanghai General Hospital, Shanghai 200080, People’s Republic of China; 2Department of Haematology, Shanghai Jiaotong University Affiliated Xinhua Hospital, Shanghai 200092, People’s Republic of China; 3Department of Haematology, Shanghai Jiaotong University Affiliated Ruijing Hospital, Shanghai 200020, People’s Republic of China; 4Department of Haematology, Fudan University Affiliated Zhongshan Hospital, Shanghai 200032, People’s Republic of China
Correspondence: Chun Wang; Hai-Tao Bai
Department of Haematology, Shanghai General Hospital, No. 100 Haining Road, Hongkou District, Shanghai 200080, People’s Republic of China
Tel +86 216 324 0090; +86 216 324 0090-3171
Fax +86 213 779 8078
Email firstname.lastname@example.org; email@example.com
Objective: The mobilization and collection of sufficient autologous peripheral blood stem cells (APBSCs) are important for the fast and sustained reconstruction of hematopoietic function after autologous transplantation. This study aims to evaluate the mobilization effect and safety of thrombopoietin (TPO) combined with chemotherapy + G-CSF for APBSCs in patients with refractory/relapsed non-Hodgkin’s lymphoma.
Methods: A total of 78 patients were included in the present study. After receiving mobilization chemotherapy, all patients were randomly divided into two groups: TPO group (n=40), patients were given subcutaneous injection of rhTPO + G-CSF, and control group (n=38), patients were given subcutaneous injection of G-CSF. The primary endpoint was the total number of obtained CD34+ cells. The secondary endpoints were the mononuclear cell count, the proportion of target and minimum mobilization, the engraftment time of neutrophils and platelets after APBSCT, the number of platelet and red blood cell infusions, the incidence of infectious fever and fever duration, and TPO-related side effects in patients.
Results: TPO participation significantly increased the total CD34+ cell count. A higher proportion of patients in the TPO group achieved the minimum and target CD34+ cells, when compared to the control group. TPO-related adverse events were not observed in either of these groups. In addition, there were no significant differences in engraftment time, the number of platelet and red blood cell transfusions, the incidence of infectious fever, and fever duration between these two groups.
Conclusion: TPO combined with chemotherapy + G-CSF can safely and effectively enhance the mobilization effect for APBSCs in patients with refractory/relapsed non-Hodgkin’s lymphoma.
Keywords: recombinant human thrombopoietin, mobilization, non-Hodgkin’s
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]